Le Lézard
Classified in: Health
Subjects: SVY, TRI

Clinical Studies of Natural Antiviral Gene-Eden-VIR/Novirin Are Listed on PubMed, the Most Selective and Prestigious Database of Medical Studies


SARASOTA, Fla., Oct. 16, 2017 /PRNewswire/ -- Many people currently use herbal treatments to improve their health. However, some are still reluctant to use those treatments.  To discover why, a study asked 601 individuals about their perceptions of natural treatments. [1]  The analysis of the answers revealed that many doubted their efficacy.  The study also discovered that even when the participants recognized this efficacy, they assumed that natural treatments have a small effect, much smaller than drugs.  Finally, the analysis revealed that the participants assumed that their doctors are against natural treatments. [1]  A perspective article added to these discoveries by writing that people commonly say that "for many of the (natural treatments) on the market there is a lack of clinical data from good quality randomized controlled trials" that proves their efficacy. [2] It is clear that to convince the public to use herbal treatments, researchers need to conduct high quality clinical studies that prove their safety and efficacy, and to compare this safety and efficacy to those of drugs. 

The Center for the Biology of Chronic Disease (CBCD) recognized this need for high quality clinical studies that prove the safety and efficacy of herbal treatments.  To address this need, a team of scientists from the CBCD, headed by Dr. Hanan Polansky, decided to conduct such studies to test two herbal treatments: Gene-Eden-VIR and Novirin. To ensure that these studies are of high quality, the team followed the FDA guidelines for conducting clinical studies.  The team also decided to submit the results to major medical journals.  The CBCD is happy to announce that this process was successful.  So far, three papers were published in two major medical journals.  In addition, the abstracts of these papers were listed on the US National Library of Medicine (PubMed). [3] [4] [5]  PubMed is the most selective and prestigious database of medical papers in the world.  Such listing indicates that the listed clinical studies are of high quality, and can be trusted by the public in making decisions about health. In fact, Lilac Corp sees this listing as a stamp of approval of the medical profession for its products.

These studies are important for three reasons. 1. They establish that the herbal treatments Gene-Eden-VIR and Novirin are safe and effective.  2. They show that herbal treatments can be better than the leading drugs.  3. The studies teach how to test herbal treatments.

For more information on the studies, visit http://cbcd.net/, and on Gene-Eden-VIR/Novirin, visit: http://no-viren.com/.

Media Contact:
Rebecca Beris
Lilac Corp
585-250-9999

http://no-viren.com/

[1] Jain N, Astin JA. Barriers to acceptance: an exploratory study of complementary/alternative medicine disuse. J Altern Complement Med. 2001 Dec;7(6):689-96.

[2] Sarah Edwards, M. Jayne Lawrence, Colin Cable and Michael Heinrich, Use and efficacy of herbal medicines: Part 2-clinical effectiveness, The Pharmaceutical Journal, Vol. 289, p270. 

[3] Polansky H, Itzkovitz E, Javaherian A. Clinical study of Gene-Eden-VIR/Novirin in genital herpes: suppressive treatment safely decreases the duration of outbreaks in both severe and mild cases, Clin Transl Med. 2016; 5: 40.

[4] Polansky H, Javaherian A, Itzkovitz E. Clinical study in genital herpes: natural Gene-Eden-VIR/Novirin versus acyclovir, valacyclovir, and famciclovir, Drug Des Devel Ther. 2016; 10: 2713?2722.

[5] Polansky H, Itzkovitz E, Javaherian A. Human papillomavirus (HPV): systemic treatment with Gene-Eden-VIR/Novirin safely and effectively clears virus. Drug Des Devel Ther. 2017 Mar 3;11:575-583. 

SOURCE Lilac Corp


These press releases may also interest you

at 02:25
SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of augmented intelligence-based solutions for skin disorders is pleased to announce a new partnership with Al Shirawi Healthcare solutions, a leading distributor of medical technologies...

at 02:20
BioInvent International (STO:BINV)"During the first quarter of the year, we continued making excellent progress with our clinical pipeline targeting TNFR2 and FcyRIIB, building on the momentum we generated during a very successful 2023. Looking...

at 01:00
PARIS, FRANCE, 24 April 2024 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its sales for the first quarter of 2024. ? ?  Q1 2024? Q1 2023? % change? ?m? ?m? ActualCER1Growth...

23 avr 2024
GenScript, a global leader in life sciences and biotechnology, successfully hosted an Open Day event at its Singapore facility on the 16th of April, welcoming more than 50 representatives from Singapore. This event provided an exclusive look into...

23 avr 2024
Cybervation, an award-winning global technology and healthcare solutions company, proudly announces that its CEO, Purba Majumder, has been distinguished as one of the 2024 100 Women to KNOW Across America. This award from KNOW Women recognizes...

23 avr 2024
The report titled "Glycated Albumin Assay Market by Product (Animal Glycated Albumin Assay, Human Glycated Albumin Assay), Application (Prediabetes, Type 1 Diabetes, Type 2 Diabetes), End User - Global Forecast 2024-2030" is now available on...



News published on and distributed by: